447 related articles for article (PubMed ID: 28718902)
1. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
Shaheen N; Shiti A; Gepstein L
Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
[TBL] [Abstract][Full Text] [Related]
3. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
Tan SH; Ye L
J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052
[TBL] [Abstract][Full Text] [Related]
4. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
Del Álamo JC; Lemons D; Serrano R; Savchenko A; Cerignoli F; Bodmer R; Mercola M
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1717-27. PubMed ID: 26952934
[TBL] [Abstract][Full Text] [Related]
5. The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.
Ye L; Ni X; Zhao ZA; Lei W; Hu S
J Cardiovasc Transl Res; 2018 Oct; 11(5):366-374. PubMed ID: 29845439
[TBL] [Abstract][Full Text] [Related]
6. Stem cells for drug screening.
Laposa RR
J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
[TBL] [Abstract][Full Text] [Related]
7. Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
Bruyneel AA; McKeithan WL; Feyen DA; Mercola M
Curr Opin Pharmacol; 2018 Oct; 42():55-61. PubMed ID: 30081259
[TBL] [Abstract][Full Text] [Related]
8. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC
Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802
[TBL] [Abstract][Full Text] [Related]
9. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
Tzatzalos E; Abilez OJ; Shukla P; Wu JC
Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
[TBL] [Abstract][Full Text] [Related]
10. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: The New Working Horse in Cardiovascular Pharmacology?
Lemoine MD; Christ T
J Cardiovasc Pharmacol; 2021 Mar; 77(3):265-266. PubMed ID: 33433138
[No Abstract] [Full Text] [Related]
11. Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes.
Bedada FB; Wheelwright M; Metzger JM
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1829-38. PubMed ID: 26578113
[TBL] [Abstract][Full Text] [Related]
12. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
Sallam K; Li Y; Sager PT; Houser SR; Wu JC
Circ Res; 2015 Jun; 116(12):1989-2004. PubMed ID: 26044252
[TBL] [Abstract][Full Text] [Related]
13. Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
Millard D; Dang Q; Shi H; Zhang X; Strock C; Kraushaar U; Zeng H; Levesque P; Lu HR; Guillon JM; Wu JC; Li Y; Luerman G; Anson B; Guo L; Clements M; Abassi YA; Ross J; Pierson J; Gintant G
Toxicol Sci; 2018 Aug; 164(2):550-562. PubMed ID: 29718449
[TBL] [Abstract][Full Text] [Related]
14. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
15. Arrhythmogenicity Test Based on a Human-Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocyte Layer.
Slotvitsky M; Tsvelaya V; Frolova S; Dementyeva E; Agladze K
Toxicol Sci; 2019 Mar; 168(1):70-77. PubMed ID: 30388253
[TBL] [Abstract][Full Text] [Related]
16. Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning.
Yang H; Zhong W; Hamidi MR; Zhou G; Liu C
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1041-1048. PubMed ID: 31518384
[TBL] [Abstract][Full Text] [Related]
17. The electrophysiological development of cardiomyocytes.
Liu J; Laksman Z; Backx PH
Adv Drug Deliv Rev; 2016 Jan; 96():253-73. PubMed ID: 26788696
[TBL] [Abstract][Full Text] [Related]
18. Human pluripotent stem cell-based cardiovascular disease modeling and drug discovery.
Liu G; Liu Z; Cao N
Pflugers Arch; 2021 Jul; 473(7):1087-1097. PubMed ID: 33686477
[TBL] [Abstract][Full Text] [Related]
19. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024
[No Abstract] [Full Text] [Related]
20. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening.
Dick E; Rajamohan D; Ronksley J; Denning C
Biochem Soc Trans; 2010 Aug; 38(4):1037-45. PubMed ID: 20659000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
